High dose sildenafil citrate induced persistent binocular anomalopia: A case report

CURRENT STATUS: POSTED

Ying Huang
The Affiliated Eye Hospital of Wenzhou Medical University

Changbiao Xu
The Affiliated Eye Hospital of Wenzhou Medical University

Qianqian Zhu
The Affiliated Eye Hospital of Wenzhou Medical University

Yikui Zhang
Taizhou Hospital of Zhejiang Province

Bing Lin
The Affiliated Eye Hospital of Wenzhou Medical University

Corresponding Author
lbing124@126.com

DOI:
10.21203/rs.2.308/v1

SUBJECT AREAS
Internal Medicine Specialties

KEYWORDS
Sildenafil citrate, high dose, anomalopia, persistent, outer layer of retina
Abstract

**Background:** When taking the recommended dose of sildenafil citrate for male erectile dysfunction (ED) and pulmonary hypertension (PAH), the incidence of ocular side effects, including a sense of blue-tinted vision and changes in brightness perception in the form of increased sensitivity to light, was 0.1–11%, and the visual symptoms were almost transient. Only a few cases reported the large dose of sildenafil citrate. The visual symptoms of these cases were all reversible. Up to now, no case was reported that the visual symptoms was irreversible, except this one.

**Case Presentation:** A 39-year-old man was sent to emergency department for taking over dosage of 800mg sildenafil citrate (trade name Viagra) to commit suicide. Visual symptoms appeared 4 hours later, including photophobia, blue halo in center field and gray stripes over red background. Sildenafil citrate toxicity caused the damage to outer layer of retina, including of myoid zone, ellipsoidal zone and interdigitation zone on OCT. Pattern visual evoked potential (P-VEP) demonstrated that the amplitudes of bilateral 1 degree spatial frequency P100 was declined mildly, and full-field electroretinogram (ERG) showed slightly-reduced amplitudes of dark-adapted ERG b-wave in both eyes. The patient was diagnosed as bilateral drug toxic retinopathy and ametropia. He was treated with compound anisodine hydrobromide. At 3-week follow-up, myoid zone, ellipsoidal zone and interdigitation zone of macular was improved on OCT, the amplitude of bilateral 1 degree spatial frequency P100 and dark-adapted ERG b-wave was improved slightly, but still remained abnormal. However, the visual symptoms did not improve any more over more than 1 year.

**Conclusions:** High dose of sildenafil may lead to irreversible death of the photoreceptor cells and permanent visual impairment. The ocular side effects of recommended dose and potential visual risks of drug overdose should be paid more attention.

**Keywords:** Sildenafil citrate, high dose, anomalopia, persistent, outer layer of retina.

**Background**

Sildenafil citrate acts as a phosphodiesterase (PDE) inhibitor. PDE-5 has been demonstrated to be present in bipolar cells, ganglion cells and the endothelial and smooth muscle cells of the vascular wall in retinal and choroidal vessels[1]. PDE-6 is a key isoenzyme located in the outer segments of
rods and cones for the conversion of light stimulation to electrical signals[2]. The relative selectivity of sildenafil for PDE-5 was 10 times of PDE-6[3].

When taking the recommended dose of sildenafil citrate for male erectile dysfunction (ED) and pulmonary hypertension (PAH), the incidence of ocular side effects, including a sense of blue-tinted vision and changes in brightness perception in the form of increased sensitivity to light, was 0.1-11% [4-7], and the visual symptoms were almost transient.

Only a few cases reported the large dose of sildenafil citrate. The visual symptoms of these cases were all reversible.

Case Presentation

A 39-year-old male patient presented to our eye hospital with complaint of binocular anomalopia over 1 week. He took 800mg (50mg×16 tablets) sildenafil citrate (trade name Viagra) which was bought on the internet, attempting to commit suicide for pressure 1 week ago. Visual symptoms appeared 4 hours later, including photophobia, blue halo in center field, gray stripes over red background, accompanied with dizziness and nausea, without vomiting and vision loss. The patient was physically healthy with no noteworthy medical history. Six hours after taking the medicine, the patient was sent to the emergency department of the second affiliated hospital of Wenzhou Medical University. After blood tests (i.e. blood count, liver and kidney function, and coagulation) and Magnetic Resonance Imaging (MRI), he was diagnosed as drug poisoning and treated with liver protection. The attending doctor then referred the patient to our hospital for his visual complaints.

Ophthalmic examination revealed his best corrected vision acuity (BCVA) was 1.0 in both eyes. Color vision examination showed anerythrochloropsia. There were no afferent pupillary defects and no apparent pathological changes in the anterior segment of either eye. Intraocular pressure was 9.9mmHg in the right eye and 11.8mmHg in the left eye. Fundus photography showed that there was a round yellow-white macular lesion with the size of approximately 2/3 papillary diameter (PD) in the right eye(figure 1-A1), and the left eye was normal(figure 1-A2). Optical coherence tomography (OCT) showed there were a focal choroidal excavation in the fovea of right eye(figure 2-A1) and disrupted myoid zone, ellipsoidal zone and interdigitation zone in the macular region of both eyes(figure 2-
A1,A2). Fundus fluorescein angiography (FFA) revealed high fluorescence in the macular of right eye (Figure 1-B1,B2), whereas the left eye was normal (Figure 1-B3). Visual field (VF) revealed a general decline of binocular sensitivity. Pattern visual evoked potential (P-VEP) demonstrated that the amplitudes of bilateral 1 degree spatial frequency P100 was declined mildly (figure 3A). Full-field electroretinogram (ERG) showed slightly-reduced amplitudes of dark-adapted ERG b-wave in both eyes (figure 4A). The patient was diagnosed as bilateral drug toxic retinopathy and ametropia. He was treated with compound anisodine hydrobromide (2ml subcutaneous injection around the superficial temporal artery) once a day for 1 week. OCT showed improved myoid zone, ellipsoidal zone and interdigitation zone of macular (figure 2-B1,B2), and the amplitude of bilateral 1 degree spatial frequency P100 and dark-adapted ERG b-wave was improved slightly, but still remained abnormal at 3-week follow-up (figure 3C, figure 4B). However, the symptom of binocular anomalopia persists over the following 1 year.

Discussion And Conclusions
When taking the recommended dose ranging of 25 to 100mg/day for male ED and 20 mg three times a day for PAH [8], the incidence of ocular side effects, including a sense of blue-tinted vision and changes in brightness perception in the form of increased sensitivity to light, was 0.1–11% [4-7]. There was a reduction in a-wave, b-wave amplitude and sensitivity of S-cone [9,10], and a prolongation of the photopic a-wave and scotopic b-wave [11]. The visual symptoms and ERG changes were almost transient [3,12], which were at peak periods in 1–2 hours and disappeared in 3–24 hours after taking sildenafil [9,13].

According to the literature, there were a few vision-threatening complications when taking recommended dose of sildenafil, including nonarteritic anterior ischemic optic neuropathy (NAION) [14-16], central retinal artery occlusion (CRAO) [17], acute angle closure glaucoma [18], pupil-sparing third nerve palsy [19], and central serous chorioretinopathy (CSC) [20]. They were more likely to be caused by the systemic or ocular hemodynamic changes following vasodilatation of retina and choroid by PED-5 inhibition.

Concerning the large dose of the drug usage, there were less reported studies and cases. Vision
symptoms occurs in 40~50% individuals when taking over a dose of 100 mg sildenafil, 50% individuals using 200mg, and 100% individuals using 600–800mg [21]. Kimet et al reported a case that a patient took 750 mg sildenafil presented blurred vision, OCT demonstrated irregularities in the photoreceptor line, his full-field and multifocal ERG were reduced in amplitudes. The toxicity of sildenafil persisted over several months in the ERG and OCT, these changes returned to normal 1 year later[22]. Izadi et al reported a patient took 1500mg dosage of sildenafil persisted the symptoms of central visual blurring and chromatopsia for 5 months, then returned to normal[23]. In our case, the patient who took 800mg sildenafil was under medical attention immediately, but his visual symptoms still existed 4 hours later. The symptoms of anomalopia and photaesthesia, and the changes of macular outer layer in OCT, were consistent with previous studies. However, the visual symptoms did not improve any more at more than 1 year. It was speculated that a higher dose of sildenafil may lead to irreversible death of the photoreceptor cells and permanent visual impairment, which differs from the previous cases of reversible vision change.

With the increasing number of sildenafil users in China, the ocular side effects of recommended dose and potential visual risks of drug overdose should be paid more attention.

Abbreviations
Abbreviations:

PDE: phosphodiesterase
ED: erectile dysfunction
PAH: pulmonary hypertension
MRI: Magnetic Resonance Imaging
BCVA: best corrected vision acuity
PD: papillary diameter
OCT: Optical coherence tomography
FFA: Fundus fluorescein angiography
VF: Visual field
P-VEP: Pattern visual evoked potential
ERG: electroretinogram

NAION: nonarteritic anterior ischemic optic neuropathy

CRAO: central retinal artery occlusion

CSC: central serous chorioretinopathy

Declarations

Ethics approval and consent to participate:

Not applicable.

Consent for publication:

The patient has read and signed the statement of the informed consent. We have obtained consent to publish from the patient to report his data including detailed medical history and clinical examination images. A copy of the written consent is available for review by the Editor of BMC Ophthalmology.

Availability of data and material:

All data generated or analyzed during this study are included in this published article.

Competing interests:

The authors declare that they have no competing interests.

Funding:

No funding was obtained for this study.

Authors' contributions

Ying Huang has made the conception of the manuscript, has contributed to analysis and interpretation of data and has been involved in drafting, writing and revising the manuscript.

Changbiao Xu has contributed to analysis and interpretation of data and has been involved in drafting the manuscript. Qianqian Zhu performed the OCT, FFA, ERG, VEP examination of the patient. Yikui Zhang has been involved in revising the manuscript. Bing Lin was the attending physician and responsible for the treatment and follow-up of the patient, has made the conception of the manuscript, has been involved in drafting and revising the manuscript and given the final approval of the version to be published. All authors read and approved the final manuscript.
Acknowledgements:
Not Applicable.

References
1. Foresta C, Caretta N, Zuccarello D, et al. Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects[J]. Eye, 2008, 22(1):144-9.
2. Lagnado L. Visual signals in the retina: from photons to synapses[J]. Experimental Physiology, 2010, 85(1):1-15.
3. Fraunfelder F W. Visual Side Effects Associated with Erectile Dysfunction Agents[J]. American Journal of Ophthalmology, 2005, 140(4):723-724.
4. Carter J E. Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?[J]. Journal of the Neurological Sciences, 2007, 262(1):89-97.
5. Cunningham A V, Smith K H. Anterior ischemic optic neuropathy associated with viagra.[J]. J Neuroophthalmol, 2001, 21(21):22-25.
6. Santaella R M, Fraunfelder F W. Ocular Adverse Effects Associated with Systemic Medications[J]. Drugs, 2007, 67(1):75-93.
7. Marmor M F, Kessler R. Sildenafil (Viagra) and Ophthalmology[J]. Survey of Ophthalmology, 1999, 44(2):153-162.
8. Hatzimouratidis K, Eardley A I, Giuliano F, et al. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation[J]. European Urology, 2010, 57(5):804-814.
9. Vobig M A, Klotz T, Staak M, et al. Retinal side-effects of sildenafil[J]. Lancet, 1999, 353(9150):375.
10. Stockman A, Sharpe L T, Tufail A, et al. The effect of sildenafil citrate (Viagra) on visual sensitivity[J]. J Vis, 2007, 7(8):4.

11. Jägle H, Jägle C, Sérey L, et al. Visual short-term effects of viagra: double-blind study in healthy young subjects ☆[J]. American Journal of Ophthalmology, 2004, 137(5):842-849.

12. Luu J K, Chappelow A V, Mcculley T J, et al. Acute effects of sildenafil on the electroretinogram and multifocal electroretinogram.[J]. American Journal of Ophthalmology, 2001, 132(3):388-394.

13. Kinoshita J, Iwata N, Shimoda H, et al. Sildenafil-induced reversible impairment of rod and cone phototransduction in monkeys.[J]. Invest Ophthalmol Vis Sci, 2015, 56(1):664.

14. Thurtell M J, Tomsak R L. Non-artertic ischemic optic neuropathy with PDE5 inhibitors for erectile dysfunction[J]. International Journal of Impotence Research, 2008, 20(6):537-543.

15. Gorkin L, Hvidsten K, Sobel R E, et al. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.[J]. International Journal of Clinical Practice, 2010, 60(4):500-503.

16. Hayreh S S. Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship?[J]. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2005, 25(4):295.

17. Akash R, Hrishikesh D, Amith P, et al. Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra.[J]. Journal of Ocular Pharmacology & Therapeutics the Official Journal of the Association for Ocular Pharmacology &
Therapeutics, 2005, 21(4):315.

18. Grunwald J E, Siu K K, Jacob S S, et al. Effect of sildenafil citrate (Viagra) on the ocular circulation.[J]. American Journal of Ophthalmology, 2002, 133(1):170-170.

19. Donahue S P, Taylor R J. Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra) ☆[J]. American Journal of Ophthalmology, 1998, 126(3):476-477.

20. Damar E, Toklu Y, Tuncel A, et al. Does therapeutic dose of sildenafil citrate treatment lead to central serous chorioretinopathy in patients with erectile dysfunction?[J]. American Journal of Mens Health, 2013, 7(5):439-443.

21. Fabbri A, Aversa A, Isidori A. Sildenafil and erectile dysfunction.[J]. Journal of Endocrinological Investigation, 1999, 22(6):486-492.

22. Kim H D, Chang J H, Kim Y K, et al. Electrophysiologic Effects of Very High-Dose Sildenafil[J]. Jama Ophthalmol, 2017, 135(2).

23. Izadi S, Silva S R D, Sculfor D, et al. ‘Persistant bilateral relative central scotomas induced by taking an excessive dose of sildenafil’[J]. Acta Ophthalmologica, 2012, 90(6):e496-e498.

Figures
Figure 1 FP and FFA.

A1, A2: FP, 2/3 PD round and yellow-white lesion in macular of right eye (A1), whereas the left eye was normal (A2). B1, B2, B3: FFA, high fluorescence in macular of right eye (B1: early stage, B2: late stage), whereas the left eye was normal (B3).

Figure 1
Figure 2 OCT
A1: right eye at the first visit, a focal choroidal excavation in fovea, myoid zone, ellipsoidal zone and interdigitation zone of macular disrupted.
A2: left eye at the first visit, myoid zone, ellipsoidal zone and interdigitation zone of macular disrupted. B1: right eye at 3-week follow-up, myoid zone, ellipsoidal zone and interdigitation zone of macular improved, but still remained abnormal. B2: left eye at 3-week follow-up, myoid zone, ellipsoidal zone and interdigitation zone of macular improved, but still remained abnormal.
Figure 3 P-VEP

A: 1.0 degree spatial frequency P-VEP at 1st visit, the amplitude of P100 was mild to moderate declined of both eyes (N75-P100 was 5.49μV of right eye and 4.84 μV of left eye, normal N75-P100 was 7.70-16.7μV). B: 15 minutes spatial frequency P-VEP at the first visit. C: 1 degree spatial frequency P-VEP at 3-weeks follow-up, the amplitude of P100 improved slightly, but still remained abnormal(N75-P100 was 7.16μV of right eye and 6.00μV of left eye, normal N75-P100 was 7.70-16.7μV). D: 15 minutes spatial frequency P-VEP at 3-weeks follow-up.
Figure 4  ERG
A: the amplitude of binocular dark-adapted ERG decreased slightly (The amplitude of scotopic 0.01 ERG b-wave was 198μV of right eye and 225μV of left eye, the amplitude of scotopic 3.0 ERG b-wave was 425μV of right eye and 474μV of left eye. Normal amplitude of scotopic 0.01 ERG b-wave was 289-437μV, normal amplitude of scotopic 3.0 ERG b-wave was 515-694μV). B: The amplitude dark-adapted ERG b-wave improved a little, but still abnormal at 3-week follow-up (The amplitude of scotopic 0.01 ERG b-wave was 232 of right eye and 241 of left eye, the amplitude of scotopic 3.0 ERG b-wave was 460μV of right eye and 476μV of left eye. Normal amplitude of scotopic 0.01 ERG b-wave was 289-437μV, normal amplitude of scotopic 0.01 ERG b-wave was 515-694μV).

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

CAREchecklist.docx